Volume 19 Issue 11
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(11): 1836-1839
XIE Wei-nan, LIU Zhi. The effect of paricalcitol on the cardiac function of secondary hyperparathyroidism patients with maintenance hemodialysis[J]. Chinese Journal of General Practice, 2021, 19(11): 1836-1839. doi: 10.16766/j.cnki.issn.1674-4152.002179
Citation: XIE Wei-nan, LIU Zhi. The effect of paricalcitol on the cardiac function of secondary hyperparathyroidism patients with maintenance hemodialysis[J]. Chinese Journal of General Practice, 2021, 19(11): 1836-1839. doi: 10.16766/j.cnki.issn.1674-4152.002179
shu

The effect of paricalcitol on the cardiac function of secondary hyperparathyroidism patients with maintenance hemodialysis

doi: 10.16766/j.cnki.issn.1674-4152.002179
  • 1.

    Graduate School of Bengbu Medical College, Bengbu, Anhui 233000, China

Funds:

 KJ2019A0095

 BYKY18174

  • Received Date: 2021-03-30
    Available Online: 2022-02-15
    Abstract
  •   Objective  To observe the changes of cardiac function related parameters in secondary hyperparathyroidism (SHPT) patients with maintenance hemodialysis (MHD) after using paricalcitol.   Methods  Forty SHPT patients with MHD in Huainan First People's Hospital from December 2019 to September 2020 were included. The clinical data, serum intact parathyroid hormone (iPTH), calcium, phosphorus and heart parameters before the treatment of paricalcitol were collected. The parameters included left ventricular ejection fraction (EF), left ventricular end-diastolic dimension (LVDd), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular end systolic diameter (LVDs), left atrium diameter (LAD), left ventricular fractional shortening (FS), left ventricular mass (LVM) and left ventricular myocardial mass index (LVMI). The changes of the above-mentioned indicators before and after the medication were compared.   Results  Compared with baseline value, the serum iPTH of SHPT patients decreased significantly at 1, 3, and 6 months after using paricalcitol (P < 0.001), and serum calcium, phosphorus, calcium and phosphorus product levels were relatively stable. After 6 months of paricalcitol treatment, there were 21 SHPT patients (52.5%) whose iPTH decreased by greater than or equal to 50%, and 28 patients (70.0%) whose iPTH decreased by greater than or equal to 30%. After 6 months of paricalcitol treatment, LVMI, LVM, IVST, LVDd, LVPWT of 40 patients decreased significantly, and FS was increased (all P < 0.01). While LAD, LVDs and EF had no change (all P>0.05). The LAD, LVMI, LVM, IVST, LVDd, LVPWT of LVH group patients were also significantly lower than before, and FS was increased (all P < 0.01). While the non-LVH group patients showed no significant change (all P>0.05).   Conclusion  Paricalcitol can significantly reduce the serum iPTH level, treat SHPT patients with MHD effectively and has fewer adverse effects. It also could subside LVH or delay its progression.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    MAJOR R W, CHENG M R I, GRANT R A, et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis[J]. PLoS One, 2018, 13(3): e0192895. doi: 10.1371/journal.pone.0192895
    [2]
    IO H, NAKATA J, INOSHITA H, et al. Relationship among left ventricular hypertrophy, cardiovascular events, and preferred blood pressure measurement timing in hemodialysis patients[J]. J Clin Med, 2020, 9(11): 3512. doi: 10.3390/jcm9113512
    [3]
    HWANG H S, CHO J S, HONG Y A, et al. Vascular calcification and left ventricular hypertrophy in hemodialysis patients: Interrelationship and clinical impacts[J]. Int J Med Sci, 2018, 15(6): 557-563. doi: 10.7150/ijms.23700
    [4]
    TAMAYO M, MARTíN-NUNES L, VAL-BLASCO A, et al. Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure[J]. Br J Pharmacol, 2020, 177(14): 3273-3290. doi: 10.1111/bph.15048
    [5]
    MASSIMETTI C, IMPERATO G, FERIOZZI S. Correction of secondary hyperparathyroidism with paricalcitol in renal transplant improves left ventricular hypertrophy[J]. G Ital Nefrol, 2019, 36(1): 2019-vol1. http://www.ncbi.nlm.nih.gov/pubmed/30758155
    [6]
    王自力, 谢良地. 左心室心肌质量的测量(续一)[J]. 中华高血压杂志, 2008, 16(4): 370-371. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ200804028.htm
    [7]
    张雪琴, 庄晶, 王喻, 等. 帕立骨化醇和骨化三醇治疗血液透析患者继发性甲状旁腺功能亢进症的疗效比较[J]. 中华肾脏病杂志, 2018, 34(10): 778-780. doi: 10.3760/cma.j.issn.1001-7097.2018.10.010
    [8]
    YETER H H, KORUCU B, BALI E B, et al. Association between calcitriol and paricalcitol with oxidative stress in patients with hemodialysis[J]. Int J Vitam Nutr Res, 2020, 17: 1-8. http://www.researchgate.net/publication/338390043_Association_between_calcitriol_and_paricalcitol_with_oxidative_stress_in_patients_with_hemodialysis_Running_title_Effects_of_vitamin_D_on_oxidative_stress
    [9]
    MARTíNEZ-ARIAS L, PANIZO S, ALONSO-MONTES C, et al. Effects of calcitriol and paricalcitol on renal fibrosis in CKD[J]. Nephrol Dial Transplant, 2021, 36(5): 793-803. doi: 10.1093/ndt/gfaa373
    [10]
    BIGGAR P, KOVARIK J, KLAUSER-BRAUN R, et al. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: A German-Austrian, single-arm, open-label, prospective, noninterventional, observational study[J]. Nephron Clin Pract, 2014, 126(1): 39-50. doi: 10.1159/000357677
    [11]
    李京, 李霞, 王怡. 帕立骨化醇治疗血液透析患者伴继发性甲状旁腺功能亢进的疗效观察[J]. 中国血液净化, 2019, 18(6): 386-389. doi: 10.3969/j.issn.1671-4091.2019.06.003
    [12]
    D'AMORE C, MARSICO F, PARENTE A, et al. Vitamin D deficiency and clinical outcome in patients with chronic heart failure: A review[J]. Nutr Metab Cardiovasc Dis, 2017, 27(10): 837-849. doi: 10.1016/j.numecd.2017.07.009
    [13]
    ZITTERMANN A, ERNST J B. Calciotropic and phosphaturic hormones in heart failure[J]. Nutr Metab Cardiovasc Dis, 2016, 26(11): 971-979. doi: 10.1016/j.numecd.2016.06.007
    [14]
    PODZOLKOV V I, POKROVSKAYA A E, PANASENKO O I. Vitamin D deficiency and cardiovascular pathology[J]. Ter Arkh, 2018, 90(9): 144-150. http://www.ncbi.nlm.nih.gov/pubmed/30701749
    [15]
    GLUBA-BRZ ZKA A, FRANCZYK B, CIA KOWSKA-RYSZ A, et al. Impact of vitamin D on the cardiovascular system in advanced Chronic Kidney Disease (CKD) and dialysis patients[J]. Nutrients, 2018, 10(6): 709. doi: 10.3390/nu10060709
    [16]
    贾静静, 赵劲东, 董平栓, 等. 补充维生素D对心力衰竭患者临床作用的Meta分析[J]. 临床心血管病杂志, 2018, 34(2): 136-141. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB201802009.htm
    [17]
    SAPONARO F, SABA A, FRASCARELLI S, et al. Vitamin D measurement and effect on outcome in a cohort of patients with heart failure[J]. Endocr Connect, 2018, 7(9): 957-964. doi: 10.1530/EC-18-0207
    [18]
    COSTANZO S, DE CURTIS A, DI CASTELNUOVO A, et al. Serum vitamin D deficiency and risk of hospitalization for heart failure: Prospective results from the Moli-sani study[J]. Nutr Metab Cardiovasc Dis, 2018, 28(3): 298-307. doi: 10.1016/j.numecd.2017.11.008
    [19]
    PANDEY A, KITZMAN D W, HOUSTON D K, et al. Vitamin D status and exercise capacity in older patients with heart failure with preserved ejection fraction[J]. Am J Med, 2018, 131(12): 1515. e11-1515. e19. doi: 10.1016/j.amjmed.2018.07.009
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (303) PDF downloads(6) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return